Febuxostat

Gout

Haiphong University of Medicine and PharmacySmall moleculePhase 4 / ApprovedActive

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 61/ 100
Competitive Position: 89/ 100

Competitive context

4 Active assets in the Gout cohort.

Asset / Sponsor	Phase	Rating
Allopurinol Haiphong University of Medicine and Pharmacy	Phase 4	B
Metformin Mostafa Bahaa	Phase 2	CCC
Abp-745 Atom Therapeutics Co., Ltd	Phase 1	CC
Marcaine Express Specialty Pharmacy	Unknown	D
DICLOFENAC Express Specialty Pharmacy	Unknown	D

View all 19 →

Same molecule, other indications

Febuxostat is also rated in:

metabolic dysfunction-associated steatotic liver diseaseActive

BB

Indicative · Phase 4

66 / 100

diastolic heart failureDormant

BB

Indicative · Phase 4

65 / 100

tumor lysis syndromeDormant

BB

Indicative · Phase 3

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.